Vor Biopharma Inc. announced a director or officer change
SEC 8-KRead source ↗
Vor Biopharma Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders0 buying, 3 selling0 purchases and 16 sales by directors and officers, last 12 monthsInsider trades
- Funds73 adding, 36 cuttingOf 30 active managers that changed their stake, 16 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Earnings running well ahead of cash (high accruals): Over the last 12 months net income exceeded operating cash flow by an amount equal to 296.8% of total assets. Earnings built on accounting accruals rather than cash have historically proved less persistent.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Vor Biopharma Inc.'s latest figures clears our strength thresholds.
Things to watch
- Share dilution. Diluted shares rose 10.7% in a year.
- Volatile shares. Over the past year the shares showed annualised volatility of 106% and a beta of 1.7 against the S&P 500.
- Insiders selling. 3 insiders sold $49M of stock over the past 365 days and none bought (0% under pre-set trading plans).
- Weak cash conversion. Free cash flow was -9% of net income over the last 12 months.
- Heavily shorted. 14.2% of the shares available to trade are sold short (5.7 days of average volume to cover).
- Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.
Latest results
- Earnings per share
- -$0.90 against an average estimate of -$0.72: missed by 25.3%
- Share reaction
- -0.2% in the first session after the results on January 12, 2026, against 0.0% for the S&P 500
- Next report
- October 30, 2026; average EPS estimate -$0.77
Price chart
- 1 day-2.2%
- 1 week+5.0%
- 1 month+3.0%
- This year+47.2%
- 1 year-20.2%
- 5 years-94.6%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- January 12, 2026
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Leadership
No model value for Vor Biopharma Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.
The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.
Valuation models
We value Vor Biopharma Inc. as an operating company, with every model that fits that kind of business. Cost of equity 12.4%: the 10-year Treasury yield (4.9%) plus a beta of 1.66 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | ~$200 ~$160–$460 | Left out: out of range vs price (10.60x) |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. | — | Combined value withheld. Review the individual models and their assumptions. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Vor Biopharma Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$6.88 | +90% | — | 0% |
| Next | −$3.67 | +47% | — | 0% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is −0.2% on 90 days ago. In the last 30 days, 1 analyst raised Vor Biopharma Inc.'s forecast and 1 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$6.90 | −$3.74 |
| 60 days ago | −$6.53 | −$3.81 |
| 30 days ago | −$6.53 | −$3.81 |
| 7 days ago | −$6.53 | −$3.80 |
| Now | −$6.88 | −$3.67 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Sept 2026 | −$0.72 | −$0.90 | −25.3% |
| Jun 2026 | −$0.70 | −$0.80 | −14.0% |
| Mar 2026 | −$0.78 | −$0.73 | +7.2% |
| Dec 2025 | −$1.19 | $307.53 | +25920.3% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 14.2% of tradable shares
- Days to cover
- 5.69 at average volume
- Short interest, 1 month
- −6% to October 15, 2026
- Held by institutions
- 87% of shares
- Held by insiders
- 9.3% of shares
- Employees
- 76 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|
| Return | |||||
| VOR | −43% | −66% | −51% | −41% | +47% |
| Industry peers (median) | −57% | −17% | −28% | −5% | −27% |
| S&P 500 | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | |||||
| VOR | 42% | 33% | 33% | 42% | 64% |
| S&P 500 | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | |||||
| VOR | −69% | −76% | −78% | −91% | −33% |
| S&P 500 | −25% | −10% | −8% | −19% | −9% |
Worst fall since February 5, 2021: 100% from February 25, 2021 to May 9, 2025. Getting back needed a 35715% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $6.86 – $25.10
- From 52-week high
- −23.3%
- vs 50-day average
- −6.9%
- vs 200-day average
- +10.9%
- Volatility (1 year)
- 106%
- Beta vs S&P 500
- 1.74
Share price after results
- Next day
- 0 up, 1 down typical move ±0.2%
- After a week
- 1 up, 0 down typical move ±30.2%
- After a month
- 0 up, 1 down typical move ±1.3%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| January 12, 2026 | −0.2% | 0.0% | +30.2% | −1.3% |
Fundamentals
Who owns it
Funds buying and selling- Reported value
- $909M
- Institutions reporting
- 102
- Shares held vs prior quarter
- ▲ 22.0%
- Positions opened / closed
- 38 / 17
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Tcg Crossover Management, LLC | $104M | 5.7M | 11.5% | 0.0% |
| FMR LLC | $90.8M | 4.9M | 10.0% | ▲ 220.3% |
| Fcpm Iii Services B.V. | $75.8M | 4.1M | 8.3% | 0.0% |
| Blackrock, Inc. | $63.8M | 3.5M | 7.0% | ▲ 336.4% |
| Venrock Adviser, LLC | $56M | 3.0M | 6.2% | 0.0% |
| State Street Corp | $48.2M | 2.6M | 5.3% | ▲ 133.9% |
| Frazier Life Sciences Management, L.P. | $46.8M | 2.5M | 5.2% | 0.0% |
| RA Capital Management, L.P. | $44.2M | 2.4M | 4.9% | ▼ 55.6% |
| Vanguard Capital Management LLC | $38.4M | 2.1M | 4.2% | ▲ 45.4% |
| Caligan Partners LP | $35.4M | 1.9M | 3.9% | 0.0% |
| Paradigm Biocapital Advisors LP | $32.2M | 1.8M | 3.5% | 0.0% |
| Great Point Partners LLC | $31.3M | 1.7M | 3.4% | ▼ 2.9% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Vor Biopharma Inc.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $49.4M 16 trades by 3 insiders · 0% under pre-set plans
Net ▼ $49.4M net selling
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Shah Rajeev M. 10% owner | July 16, 2026 | Sell | 213 | $19.75 | $4,207 |
| Shah Rajeev M. Director | April 22, 2026 | Sell | 165,150 | $15.77 | $2.6M |
| Ra Capital Management, L.P. Director | April 20, 2026 | Sell | 171,963 | $15.77 | $2.7M |
| Ra Capital Management, L.P. Director | April 17, 2026 | Sell | 458,411 | $16.28 | $7.5M |
| Ra Capital Management, L.P. Director | April 15, 2026 | Sell | 53,644 | $16.01 | $858,840 |
| Ra Capital Management, L.P. Director | April 14, 2026 | Sell | 153,735 | $15.97 | $2.5M |
| Ra Capital Management, L.P. Director | April 13, 2026 | Sell | 530,610 | $16.15 | $8.6M |
| Shah Rajeev M. Director | April 10, 2026 | Sell | 828 | $15.75 | $13,041 |
| Shah Rajeev M. Director | April 9, 2026 | Sell | 135,201 | $16.59 | $2.2M |
| Shah Rajeev M. Director | April 8, 2026 | Sell | 353,242 | $16.32 | $5.8M |
| Shah Rajeev M. Director | April 8, 2026 | Sell | 130,862 | $16.91 | $2.2M |
| Kolchinsky Peter Director | April 6, 2026 | Sell | 537,754 | $16.51 | $8.9M |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
- January 12, 2026
Recent SEC filings
- 10-Q Quarterly report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- S-3 S-3
- DEF 14A Proxy statement
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Vor Biopharma Inc. in brief
- What does Vor Biopharma Inc. do?
- Vor Biopharma Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Vor Biopharma Inc.'s stock ticker?
- Vor Biopharma Inc. trades under the ticker VOR on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Vor Biopharma Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Tcg Crossover Management, LLC, FMR LLC and Fcpm Iii Services B.V. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Vor Biopharma Inc. stock?
- Over the last 12 months, Vor Biopharma Inc.'s directors and officers reported 0 open-market purchases and 16 sales on Form 4. The insider trading page charts every trade.
Follow research on Vor Biopharma Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.